22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Development of TAP, a non-invasive test for qualitative and quantitative measurements of biomarkers from the skin surface

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The skin proteome contains valuable information on skin condition, but also on how skin may evolve in time and may respond to treatments. Despite the potential of measuring regulatory-, effector- and structural proteins in the skin for biomarker applications in clinical dermatology and skin care, convenient diagnostic tools are lacking. The aim of the present study was to develop a highly versatile and non-invasive diagnostic tool for multiplex measurements of protein biomarkers from the surface of skin.

          Results

          The Transdermal Analyses Patch (TAP) is a novel molecular diagnostic tool that has been developed to capture biomarkers directly from skin, which are quantitatively analyzed in spot-ELISA assays. Optimisation of protocols for TAP production and biomarker analyses makes TAP measurements highly specific and reproducible. In measurements of interleukin-1α (IL-1α), IL-1 receptor antagonist (IL-1RA) and human β-defensin (hBD-1) from healthy skin, TAP appears far more sensitive than skin lavage-based methods using ELISA. No side-effects were observed using TAP on human skin.

          Conclusion

          TAP is a practical and valuable new skin diagnostic tool for measuring protein-based biomarkers from skin, which is convenient to use for operators, with minimal burden for patients.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

          Biological agents have dramatically improved treatment options for patients with severe psoriasis. Etanercept (tumor necrosis factor [TNF] receptor–immunoglobulin fusion protein) is an effective treatment for many psoriasis patients, and blockade of TNF is considered to be its primary action. However, in this clinical trial, we show that etanercept has early inhibitory effects on a newly appreciated type of T cells: T helper type 17 (Th17) cells. Etanercept reduced the inflammatory dendritic cell products that drive Th17 cell proliferation (interleukin [IL] 23), as well as Th17 cell products and downstream effector molecules (IL-17, IL-22, CC chemokine ligand 20, and β-defensin 4). In contrast, Th1 cellular products and effector molecules (interferon γ, lymphotoxin α, and myxovirus resistance 1) were reduced late in disease resolution. This study suggests a role for Th17 in addition to Th1 cells in the pathogenesis of psoriasis. Th17 cells may be particularly important in driving epidermal activation in psoriatic plaques, whereas Th1 cells must also be eliminated for final disease resolution.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis

            Background: Chronic plaque-type psoriasis is a major dermatosis, but a significant question is still unanswered: What defines severity in chronic plaque-type psoriasis? While objective assessments like the Psoriasis Area and Severity Index (PASI) have frequently been used in clinical trials, quality of life (QOL) questionnaires are currently becoming more and more popular. Objective: This article summarizes the most important objective and subjective measurements of severity in psoriasis. For every dermatologist it is critically important to distinguish between severe psoriasis and psoriasis that severely affects QOL. Even if the PASI also has disadvantages, it is the most adequate instrument available to evaluate severity in plaque-type psoriasis. Result: We provide reasons why PASI >12 defines severe, PASI 7–12 moderate and PASI <7 mild chronic plaque-type psoriasis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.

              Clinical signs are a core outcome domain for atopic dermatitis (AD) trials. The current lack of standardization of outcome measures in AD trials hampers evidence-based communication.
                Bookmark

                Author and article information

                Contributors
                kadri.orro@fibrotx.com
                olga.smirnova.tallinn@gmail.com
                jelena.arshavskaja@fibrotx.com
                kristiina.salk@fibrotx.com
                anne.meikas@gmail.com
                susan@protobios.com
                reet.rumvolt@ttu.ee
                kylli.kingo@kliinikum.ee
                aram.kazarjan@fibrotx.com
                toomas.neuman@fibrotx.com
                Pieter.Spee@fibrotx.com
                Journal
                Biomark Res
                Biomark Res
                Biomarker Research
                BioMed Central (London )
                2050-7771
                13 November 2014
                2014
                : 2
                : 20
                Affiliations
                [ ]FibroTx LLC, Mäealuse 4, 12918 Tallinn, Estonia
                [ ]Dermatology Clinic, Tartu University Hospital, Raja 31, 50407 Tartu, Estonia
                [ ]PS! Pharmaconsult, Møllemoseparken 44, 3450 Allerød, Denmark
                Article
                50
                10.1186/2050-7771-2-20
                4362816
                25785188
                6600eeca-ac32-4955-902e-d6dcd6a64b16
                © Orro et al.; licensee BioMed Central Ltd. 2014

                This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 14 August 2014
                : 2 October 2014
                Categories
                Methodology
                Custom metadata
                © The Author(s) 2014

                biomarker,dermatology,skin care,diagnostics,transdermal analyses patch,interleukin 1α,interleukin 1ra,cxcl-1,cxcl-2,β-defensin-1

                Comments

                Comment on this article